Revvity Past Earnings Performance
Past criteria checks 1/6
Revvity has been growing earnings at an average annual rate of 0.4%, while the Life Sciences industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 0.5% per year. Revvity's return on equity is 2.3%, and it has net margins of 6.7%.
Key information
0.4%
Earnings growth rate
-1.7%
EPS growth rate
| Life Sciences Industry Growth | 36.9% |
| Revenue growth rate | 0.5% |
| Return on equity | 2.3% |
| Net Margin | 6.7% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Revvity makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 2,726 | 183 | 960 | 210 |
| 31 Dec 23 | 2,751 | 180 | 942 | 217 |
| 01 Oct 23 | 2,796 | 213 | 923 | 217 |
| 02 Jul 23 | 2,837 | 250 | 927 | 217 |
| 02 Apr 23 | 3,024 | 353 | 942 | 216 |
| 01 Jan 23 | 3,312 | 513 | 940 | 222 |
| 02 Oct 22 | 3,599 | 599 | 1,001 | 222 |
| 03 Jul 22 | 3,748 | 637 | 989 | 219 |
| 03 Apr 22 | 3,483 | 694 | 885 | 195 |
| 02 Jan 22 | 3,828 | 889 | 854 | 200 |
| 03 Oct 21 | 4,155 | 1,086 | 893 | 197 |
| 04 Jul 21 | 4,257 | 1,155 | 893 | 197 |
| 04 Apr 21 | 4,438 | 1,074 | 961 | 217 |
| 03 Jan 21 | 2,663 | 631 | 729 | 146 |
| 04 Oct 20 | 3,234 | 412 | 887 | 196 |
| 05 Jul 20 | 2,977 | 294 | 866 | 191 |
| 05 Apr 20 | 2,887 | 226 | 845 | 190 |
| 29 Dec 19 | 2,884 | 228 | 833 | 189 |
| 29 Sep 19 | 2,835 | 235 | 806 | 194 |
| 30 Jun 19 | 2,802 | 251 | 794 | 197 |
| 31 Mar 19 | 2,783 | 247 | 790 | 196 |
| 30 Dec 18 | 2,778 | 237 | 809 | 194 |
| 30 Sep 18 | 2,663 | 128 | 761 | 180 |
| 01 Jul 18 | 2,543 | 149 | 719 | 166 |
| 01 Apr 18 | 2,387 | 147 | 667 | 152 |
| 31 Dec 17 | 2,257 | 157 | 615 | 139 |
| 01 Oct 17 | 2,182 | 258 | 587 | 135 |
| 02 Jul 17 | 2,142 | 215 | 580 | 129 |
| 02 Apr 17 | 2,132 | 210 | 584 | 128 |
| 01 Jan 17 | 2,116 | 216 | 585 | 124 |
| 02 Oct 16 | 1,999 | 198 | 574 | 108 |
| 03 Jul 16 | 2,048 | 199 | 583 | 110 |
| 03 Apr 16 | 2,076 | 190 | 583 | 110 |
| 03 Jan 16 | 2,105 | 189 | 586 | 113 |
| 04 Oct 15 | 2,263 | 176 | 661 | 127 |
| 28 Jun 15 | 2,241 | 164 | 657 | 126 |
| 29 Mar 15 | 2,234 | 167 | 656 | 124 |
| 28 Dec 14 | 2,070 | 130 | 648 | 108 |
| 28 Sep 14 | 2,221 | 203 | 576 | 123 |
| 29 Jun 14 | 2,201 | 201 | 577 | 124 |
| 30 Mar 14 | 2,185 | 176 | 579 | 128 |
| 29 Dec 13 | 2,158 | 174 | 581 | 132 |
| 29 Sep 13 | 2,139 | 85 | 622 | 133 |
| 30 Jun 13 | 2,126 | 73 | 627 | 134 |
Quality Earnings: 0KHE has a large one-off loss of $155.0M impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: 0KHE's current net profit margins (6.7%) are lower than last year (11.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0KHE's earnings have grown by 0.4% per year over the past 5 years.
Accelerating Growth: 0KHE's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 0KHE had negative earnings growth (-48.6%) over the past year, making it difficult to compare to the Life Sciences industry average (6.5%).
Return on Equity
High ROE: 0KHE's Return on Equity (2.3%) is considered low.